Rationale for Correct Answer

The correct answer is: Approved for NTRK-positive solid tumors and ROS1-positive NSCLC

Entrectinib is FDA approved for:

  • NTRK-positive solid tumors without a known resistance mutation; metastatic, or where surgical resection is likely to result in severe morbidity; and that have progressed following treatment or have no satisfactory alternative therapy
  • ROS1-positive metastatic NSCLC

Entrectinib is not approved for use in ALK-positive NSCLC.

U.S. Food & Drug Administration (FDA). Oncology (Cancer) / Hematologic Malignancies Approval Notifications. Reviewed June 20, 2023. Accessed June 20, 2023. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm